5. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. (2006)106(7):1569-80. 6. Dunleavy...
[7] Friis AM, Gyllensten K, Aleman A,et al.The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients[J].Viruses,2010,2(4):867-879. [8] Diamantopoulos PT,Polonyfi K,Sofotasiou M,et al.Ri...
关键词异基因造血干细胞移植;EBV感染;利妥昔单抗;小剂量中图分类号R614文献标识码A文章编号2095-0616(2022)02-0024-05Analysisontheefficacyoflow-doserituximabinthetreatmentofEBVinfectionafterhematopoieticstemcelltransplantationZHANGXiaohanCAIYunWANGPengchengFANJingchao 3、CHENShiyuDUXinDepartmentofHematology,theSecond...
[ 关键词 ] 异基因造血干细胞移植;EBV 感染;利妥昔单抗;小剂量 [ 中图分类号 ] R614 [ 文献标识码 ] A [ 文章编号 ] 2095-0616(2022)02-0024-05 Analysis on the efficacy of low-dose rituximab in the treatment of EBV infection after hematopoietic stem cell transplantation ZHANG Xiaohan CAI Yun...
§:yQ!..堑z旦生』 rituximaberiectiveintheinitialtreatmentofEpstein—Barrvirus— 1992.89(21):9991—9995. positive natural killer cell lymphoproliferative disease— [10]SovinzP,SchwingerW,Lackner H,eta1.Severeepstein—barr associated J virus encephalitis with hemophagocytic syndrome:rapid hemophagocytic ...
Rituximab-containing immunochemotherapy significantly improves the prognosis of patients with EBV-DLBCL, however, the optimal first-line treatment for EBV+DLBCL-NOS still needs to be further explored. The current understanding of EBV+DLBCL-NOS, a rare subtype of DLBCL, is very limited because of ...
针对CD20的嵌合单克隆抗体利妥昔单抗(Rituximab)是可能的治疗选择,其耗 + 竭过度增殖的CD20B细胞。在前述疗法失败的情况下,CHOP化学疗法是一种另外的疗法选 择(多柔比星(doxorubicin)、环磷酰胺、长春新碱(vincristine)、泼尼松(prednisone))。 利妥昔单抗和CHOP化学疗法也可以联合,被称为R‑CHOP。偶尔,手术或...
Rituximab in the treatment of EBV infection and post-transplantation lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, prospective, clinical study,Shanghai Children's Medical Center affiliated to Shangh
ication ar Effective only agai nst lytic Immunotherapy Vaccination Recombinant gp350-based epitope peptide-based vacc Treatment of disease Monoclonal antibody agair antibody (Rituximab); EB\ cells from donor or ex vivo CTLs from patients aiid inf 清除EBV感染方法小 结 1.EBV 感染在成人中逐渐增多...
5、 group (n=60, rituximab+chop regimen) , according to different treatment methods. the curative effect, survival rate, progress!on-free survival rate and adverse reactions were compared between the two groups. results the total effective rate of clinical treatment in observation group was 91.67...